Voyager Therapeutics Inc. (VYGR) Stock Rating Reaffirmed by Wedbush
Voyager Therapeutics Inc. (NASDAQ:VYGR)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research report issued on Thursday. They currently have a $36.00 target price on the stock. Wedbush’s price target points to a potential upside of 194.12% from the company’s current price.
Several other research analysts also recently commented on the company. Stifel Nicolaus assumed coverage on Voyager Therapeutics in a research note on Thursday, July 14th. They set a “buy” rating and a $33.00 target price on the stock. Zacks Investment Research downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 26th. Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday. Finally, Piper Jaffray Cos. set a $37.00 target price on Voyager Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $26.80.
Voyager Therapeutics (NASDAQ:VYGR) opened at 12.24 on Thursday. Voyager Therapeutics has a 1-year low of $8.12 and a 1-year high of $30.54. The firm’s market cap is $327.15 million. The stock has a 50 day moving average price of $12.15 and a 200 day moving average price of $12.92.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. Voyager Therapeutics had a negative net margin of 195.31% and a negative return on equity of 20.15%. On average, analysts anticipate that Voyager Therapeutics will post ($1.48) EPS for the current year.
A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Voyager Therapeutics by 1,487.3% in the second quarter. Vanguard Group Inc. now owns 312,593 shares of the company’s stock worth $3,436,000 after buying an additional 292,900 shares during the period. JPMorgan Chase & Co. raised its stake in Voyager Therapeutics by 171.3% in the second quarter. JPMorgan Chase & Co. now owns 288,425 shares of the company’s stock worth $3,170,000 after buying an additional 182,125 shares during the period. BlackRock Fund Advisors raised its stake in Voyager Therapeutics by 106.8% in the second quarter. BlackRock Fund Advisors now owns 302,971 shares of the company’s stock worth $3,330,000 after buying an additional 156,443 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in Voyager Therapeutics during the first quarter worth about $873,000. Finally, State Street Corp raised its stake in Voyager Therapeutics by 147.1% in the second quarter. State Street Corp now owns 142,611 shares of the company’s stock worth $1,565,000 after buying an additional 84,906 shares during the period. Institutional investors own 39.65% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.